We compared α-LGR5 internalisation with that of the α-HER2 antibody (Trastuzumab) and show >90% target internalisation of α-LGR5 within 5 min whereas <50% of Trastuzumab was internalised by tumour cells after 3 h. Here, ERBB2 is linked to neoplasm.